Healthy is Lifestyle

Eribulin is a new chemotherapy drug for breast cancer patients found by researchers at the Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology in Barcelona, Spain. The research showed that the breast cancer patients given eribulin can prolong life on average 2.5 months longer than patients who did not receive this treatment.

The research published online at The Lancet has involved 508 women who were given eribulin and 254 women who received medical treatment options such as hormones or biological treatment approved for cancer treatment, radiotherapy or symptomatic treatment only. Eribulin also beneficial for the survival for patients with metastatic breast cancer.

The results of this study is expected to develop the progress of cancer treatment methods with knowing more benefits from the use eribulin for cancer treatment. The study will also further examine about the benefits of eribulin for women who have not received any treatment.